BreastScreen Norway (Mammografiprogrammet) is a population-based, nation-wide screening program for breast cancer. The program offers biennial mammographic screening to all women aged 50-69, based on their personal identification number. The program aims to detect breast cancer at an early stage, reducing mortality from the disease and enabling less invasive treatments. As part of the EuCanScreen Joint Action, Norway’s approach might serve as a model for high-quality, evidence-based screening.
Participation rate in each screening round have been stable at about 75% since start-up of the program in 1996, while 84% of the invited women have attended at least once over a ten-year period. The program has demonstrated a reduction in breast cancer mortality, with estimates of 20-30% decrease in breast cancer deaths among women invited (intention to treat) and about 40% reduction among those who have attended the program once or more (per protocol). Early detection and improved treatment are considered the main reasons for the reduced mortality.
How BreastScreen Norway works:
BreastScreen Norway involves multiple stakeholders who collaborate to ensure effective planning, performance, and quality assurance.
BreastScreen Norway aims to be in the forefront of quality improvement and research in breast cancer screening, with a strong emphasis on improving accuracy and efficiency through advanced technologies and personalised screening approaches.
Read about our research here: https://www.kreftregisteret.no/en/screening/BreastScreen_Norway/research-in-breastscreen-norway/
In November 2024 BreastScreen Norway launched a randomised controlled trial on AI in mammographic screening. The study will include 140,000 women aged 50-69, the target group for the screening program. Led by Solveig Hofvind, head of BreastScreen Norway, the study aims to determine whether AI can match or surpass radiologists in detecting breast cancer.
Initially implemented in Western Norway (Helse Vest), the study will later expand nationwide. Hofvind highlights that the results could pave the way for expanding screening age groups and tailoring screening frequency based on individual risk.
“With increasing breast cancer incidence in both younger and older women, and limited radiologist resources, we need solutions to ensure a modern and effective screening program,” says Hofvind.
Previous studies have shown AI can detect the same breast cancer tumours as radiologists, even identifying small tumours at an early stage. However, these studies were based on retrospective data. This new trial is the first in Norway to test AI as an integrated tool for radiologists in real-time screening.
Women participating in the study will be randomly assigned to have their ammograms interpreted either by AI in combination with one or two radiologists or by the standard method of two radiologists independently reviewing the images. The screening process itself remains unchanged; only the image interpretation differs.
BreastScreen Norway is also exploring risk-stratified screening, moving away from a one-size-fits-all approach.
A major study evaluated AI’s ability to predict breast cancer risk years before diagnosis. Researchers applied an AI algorithm to mammographic images from nearly 120,000 women screened between 2004 and 2018. The findings revealed that the AI-generated risk score was significantly higher for women who later developed breast cancer, with the affected breast showing nearly twice the AI score of the opposite breast, even four to six years before a clinical diagnosis. These results suggest AI could play a vital role in risk stratification, allowing for more personalised screening strategies, offering high-risk women more frequent monitoring while reducing unnecessary screening for low-risk individuals. DOI: 10.1001/jamanetworkopen.2024.37402
Norway benefits from a comprehensive cancer registry and digital health infrastructure, allowing seamless integration of screening data with patient records. This enables large-scale epidemiological research and quality monitoring.
Norway actively collaborates with European partners to share best practices and research insights. Future directions for BreastScreen Norway include:
The general objective of EUCanScreen is to assure sustainable implementation of high-quality screening for breast, cervical and colorectal cancers, as well as implementation of the recently recommended screening programs – for lung, prostate and gastric cancers. EUCanScreen will facilitate the reduction of cancer burden and achieving equity across the EU.
This project has received funding from the European Union’s EU4HEALTH Programme under the Grant Agreement no 101162959